January 30, 2012
CONTACT: Holly Auer
Four-Week Vaccination Regimen Knocks Out Early Breast Cancer Tumors, Penn Researchers Report
Majority of Patients Treated Develop Strong, Lasting Immune Responses
PHILADELPHIA -- Researchers at the Perelman School of Medicine and the Abramson Cancer Center at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient’s own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer. More than 85 percent of patients treated appear to have a sustained immune response after vaccination, which may reduce their risk of developing a more invasive cancer in the future. The results of the study were published online this month of Cancer and in the January issue of the Journal of Immunotherapy.
The researchers say the results provide new evidence that therapeutic breast cancer vaccines may be most effective for early, localized disease, and when the treatment attacks a protein critical to cancer cell survival.
“I think these data more than prove that vaccination works in situations where the target is right,” says the study’s leader, Brian Czerniecki, MD, PhD, surgical director of the Rena Rowan Breast Center and Surgical Director of the Immunotherapy Program for the Abramson Cancer Center. “Previous vaccines targeted tissue antigens that were expressed on the cancer cells, but were not necessary for tumor survival. So a vaccine response would cause the tumor to just stop expressing the antigen and the tumor would be fine. Here we’re going after HER2/neu, which is critical for survival of early breast cancers. If we knock it out with the immune response, we cripple the tumor cells.”
Czerniecki and colleagues enrolled 27 women with HER2-positive DCIS. They isolated specialized white cells from the patients’ blood using standard apheresis techniques similar to the blood donation process. Once isolated, the researchers activated the dendritic cells, which are key regulators of the immune system, and primed them with small pieces of the HER2/neu protein in Penn’s Clinical Cell and Vaccine Production Facility. Each patient then received four shots, one week apart, of their personalized anti-HER2 vaccine. And two weeks later patients had surgery to remove any remaining disease, which is standard care for DCIS patients.
The new approach has several critical advantages, compared to testing a vaccine in patients with more advanced disease. First, the activated immune cells have fewer tumor cells to kill. Second, patients’ immune systems are still responsive, unlike advanced cancer patients whose immune systems have been suppressed by their disease. Third, the investigators are able to see results quickly, by looking at serum and tumor biomarkers.
In fact, when the team compared pre-vaccination biopsy samples with post-vaccination surgical samples, they saw dramatic changes: Five patients had no disease visible at the time of surgery, indicating that their immune system had wiped out the tumor. Of the remaining 22 patients, HER2 expression was eliminated in half (11 patients), and reduced by 20 percent or more in another two. “We are continuing to see this pattern in our second, ongoing trial,” Czerniecki says.
When the team looked at immune responses, they found that 85 percent of patients had HER2-reactive CD4 and CD8 T cells, suggesting that the patients developed a robust and relatively complete immune response after vaccination. Importantly, some patients maintained their immune responses as long as 52 months, which means that they continue to have some protection from recurrence of HER2-positive disease – a key insurance policy for patients, since doctors currently are unable to accurately predict which women are likely to develop invasive breast cancer following a DCIS diagnosis.
The results of the study show the vaccine is safe and relatively easy for the women, with only low-grade side effects. The most common side effects were malaise (72 percent), injection site soreness (59 percent), chills or rigors (38 percent), fever (28 percent) and headaches (24 percent).
While the numbers of patients treated in the trial are relatively small, Czerniecki thinks they will have some idea whether the vaccination reduces the risk of disease recurrence within the next two years. In the meantime, the team continues enrolling patients in a larger study, is designing another study to test the approach in women with early invasive breast cancer, and also plans to test vaccination with additional antigens, including HER3 and HER1.
“I think if we target several of the HER2 family members, we’ll drive the tumor to a place where it has nowhere to go,” Czerniecki says. “Basically, we’ll push it over a cliff because those pathways are critical for tumor survival.”
Czerniecki notes that what the team is learning in DCIS is applicable to invasive breast cancer, and to other solid tumors that rely on the HER family of signaling proteins, including melanoma, lung, brain, and colon cancers.
Co-authors include Anupama Sharma, MD, Ursula Koldovsky, PhD, Shuwen Xu, MD, Rosemarie Mick, MS, Robert Roses, MD, Elizabeth Fitzpatrick, BS, Susan Weinstein, MD, Harvey Nisenbaum, MD, Bruce L. Levine, MD, Kevin Fox, MD, and Paul Zhang, MD, PhD from Penn, and Gary Koski, PhD, from Kent State University in Ohio.
This study was funded by an NIH grant (R01 CA096997), the Harrington Foundation, Pennies in Action, and the Mistler Foundation.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.